Average Mkt Cap
#21 of 49
$18 B
Average CAGR
#21 of 49
22 %
RPM technology can be used to monitor patients with chronic conditions like heart disease and diabetes from the comfort of their own homes. This can help reduce the number of hospital readmissions and improve patient outcomes. Telehealth services can be used in conjunction with RPM technology to allow patients to communicate with providers remotely and receive medical advice and support.
0 FDA approvals in Remote Patient Monitoring (RPM)
Improved Access to Care
"RPM technology enables remote monitoring of patients, increasing access to care for those who may have difficulty traveling to in-person appointments." - Journal of Medical Internet Research, December 2021
Cost Savings
"RPM can lead to cost savings by reducing hospital readmissions and emergency department visits, as well as enabling earlier interventions and preventing complications." - American Journal of Managed Care, January 2022
Improved Outcomes
"RPM has been shown to improve outcomes for a variety of chronic conditions, such as heart failure and diabetes, by providing real-time monitoring and intervention." - Journal of Clinical Medicine, February 2022
Investor sentiment
MarketsandResearchJune 2021
"...The global remote patient monitoring market is projected to grow at a CAGR of over 13% during the period 2021-2026, driven by the increasing prevalence of chronic diseases and the growing demand for home-based services, the rising adoption of telemedicine and mHealth technologies, and the growing investments in IT infrastructure."
Fortune Business InsightsJuly 2021
"...The global remote patient monitoring market size was valued at $7.3 billion in 2020 and is expected to reach $31.3 billion by 2028, driven by the increasing prevalence of chronic diseases, the growing demand for home-based services, and the rising adoption of telemedicine and mHealth technologies."
Global Market InsightsJune 2021
"...The remote patient monitoring market is expected to grow at a CAGR of 14.2% from 2021 to 2027, driven by the increasing demand for home-based services, the growing prevalence of chronic diseases, and the rising adoption of mHealth and telemedicine technologies."
Sector leaders
Biofourmis
Biofourmis is a Boston-based digital therapeutics company that develops AI-powered biosensors that help physicians monitor patients remotely. It recently announced that it has secured $100 million in funding to accelerate its digital therapeutics business.
iRhythm Technologies
iRhythm Technologies, a San Francisco-based digital company, has developed wearable heart monitoring technology that leverages AI and machine learning to detect cardiac arrhythmias in real time. The company has received FDA approval for its Zio XT remote heart monitoring system.
Medtronic
Medtronic, a Dublin-based medical technology company, offers a range of RPM products, including its MiniMed Connect system for remote monitoring of diabetes patients and its CareLink system for remote management of patients with chronic conditions.
